ClinConnect ClinConnect Logo
Search / Trial NCT00578929

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

Launched by ALCON RESEARCH · Dec 19, 2007

Trial Information

Current as of July 22, 2025

Completed

Keywords

Allergic Rhinitis Allergies Seasonal Allergies

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female; minimum of 6 years of age and less than 12 years
  • 2 year history of seasonal allergic rhinitis
  • Exclusion Criteria:
  • Concurrent disease that might interfere with the investigation or evaluation of te study medication
  • Confirmed diagnosis of chronic rhinosinusitis within the last year
  • Asthma, with the exception of mild intermittent asthma
  • Anatomical nasal deformity
  • Nasal obstruction
  • Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)
  • Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids
  • Ocular disorder other that allergic conjunctivitis

About Alcon Research

Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.

Locations

Kenilworth, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Ed Tumaian

Study Director

ed.tumaian@alconlabs.com

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials